Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis

(2018) Curdin Conrad et al.   Nature Communications

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

(2018) Ronald F van Vollenhoven et al.   LANCET

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

(2018) Kim Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

(2017) Daniella M. Schwartz et al.   NATURE REVIEWS DRUG DISCOVERY

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

(2017) Richard Furie et al.   Arthritis & Rheumatology

Tyrosine kinase 2 is not limiting human antiviral type III interferon responses

(2016) Sebastian Fuchs et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity

(2016) C. A. Dendrou et al.   Science Translational Medicine

Influence ofTYK2in systemic sclerosis susceptibility: a newlocusin the IL-12 pathway

(2015) Elena López-Isac et al.   ANNALS OF THE RHEUMATIC DISEASES

Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain

(2015) John S. Tokarski et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome

(2015) Alexandra Y. Kreins et al.   JOURNAL OF EXPERIMENTAL MEDICINE

TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits

(2015) Dorothée Diogo et al.   PLoS One

Aldara®-induced skin inflammation: studies of patients with psoriasis

(2014) H. Vinter et al.   BRITISH JOURNAL OF DERMATOLOGY

Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation

(2014) Michael T. Dill et al.   JOURNAL OF CLINICAL INVESTIGATION

Elevated signal transducers and activators of transcription 1 correlates with increased C-C motif chemokine ligand 2 and C-X-C motif chemokine 10 levels in peripheral blood of patients with systemic lupus erythematosus

(2014) Paul R Dominguez-Gutierrez et al.   ARTHRITIS RESEARCH & THERAPY

Modular Transcriptional Repertoire Analyses of Adults With Systemic Lupus Erythematosus Reveal Distinct Type I and Type II Interferon Signatures

(2014) Laurent Chiche et al.   Arthritis & Rheumatology

Pharmacogenomics and Translational Simulations to Bridge Indications for an Anti-Interferon-α Receptor Antibody

(2013) B Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Cross-Species Transcriptional Network Analysis Defines Shared Inflammatory Responses in Murine and Human Lupus Nephritis

(2012) C. C. Berthier et al.   JOURNAL OF IMMUNOLOGY

Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility

(2011) N. Couturier et al.   BRAIN

Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis

(2011) Daniela Fenoglio et al.   CLINICAL IMMUNOLOGY

Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity

(2011) Qian Wu et al.   ARTHRITIS RESEARCH & THERAPY

The use of ustekinumab in autoimmune disease

(2010) Caitriona Ryan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes

(2009) Q.-Z. Li et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling

(2009) Katia Boniface et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Deficiency of Type I IFN Receptor in Lupus-Prone New Zealand Mixed 2328 Mice Decreases Dendritic Cell Numbers and Activation and Protects from Disease

(2009) H. Agrawal et al.   JOURNAL OF IMMUNOLOGY

The Pronounced Th17 Profile in Systemic Sclerosis (SSc) Together with Intracellular Expression of TGFβ and IFNγ Distinguishes SSc Phenotypes

(2009) Timothy R. D. J. Radstake et al.   PLoS One

Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis a Th17 disease?

(2008) Maki Murata et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Type I Interferon: Potential Therapeutic Target for Psoriasis?

(2008) Yihong Yao et al.   PLoS One